Altamira Therapeutics announces publication of results from Bentrio trial

Altamira Therapeutics nnounced the publication of the detailed results from its clinical trial with Bentrio nasal spray in house dust mite allergic rhinitis. The peer-reviewed article was published in Clinical and Translational Allergy, one of the leading journals in the field of allergology. The HDM trial enrolled 37 patients in Canada with a history of perennial allergic rhinitis who underwent controlled allergen exposure three times in a challenge chamber for three hours each. They were randomly assigned in an open label crossover design to receive either Bentrio in a single or double dose, or no treatment, prior to allergen exposure. The primary endpoint was the change in the Total Nasal Symptom Score from baseline. The ANCOVA model demonstrated that Bentrio treatment reduced the increase in mean TNSS during the 3-hour exposure by 1.1 points vs. no treatment. Under Bentrio treatment, the mean TNSS was 4.1 points vs. 5.2 points under no treatment. Administering two sprays rather than one puff did not yield any additional treatment benefits, confirming that a single application provides ample protection. A significant majority of study participants rated global tolerability of the treatment as good or very good.